Clinical Trial: NCT05601973
Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | ETOP IBCSG Partners Foundation |
| Information Provided By: | ETOP IBCSG Partners Foundation |
| Last Update Posted: | 2026-11-12 |
Study Overview
Brief Summary
AMAZE-lung is a multicenter single-arm phase II trial. The protocol treatment consists of amivantamab, lazertinib and bevacizumab (Zirabev®), given in a three-weekly regimen. The primary objective of the trial is to assess the efficacy of amivantamab and bevacizumab added to continued treatment with the third-generation EGFR-TKI lazertinib, in patients with EGFR-mutant advanced NSCLC, who have been previously treated with a third-generation EGFR-TKI in order to provide data on treatment effect and sample size required for a future phase III trial.
In addition, the safety of the treatment combination will be evaluated.
Official Title
Conditions
Intervention / Treatment
- Drug: Amivantamab
- Drug: Lazertinib
- Drug: Zirabev
Other Study ID Numbers
- ETOP 18-21
- 2021-002337-42
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Estimated)
Study Type
Phase
| Lead Sponsor: | ETOP IBCSG Partners Foundation |
| Information Provided By: | ETOP IBCSG Partners Foundation |
| Last Update Posted: | 2026-11-12 |
Study Overview
Brief Summary
AMAZE-lung is a multicenter single-arm phase II trial. The protocol treatment consists of amivantamab, lazertinib and bevacizumab (Zirabev®), given in a three-weekly regimen. The primary objective of the trial is to assess the efficacy of amivantamab and bevacizumab added to continued treatment with the third-generation EGFR-TKI lazertinib, in patients with EGFR-mutant advanced NSCLC, who have been previously treated with a third-generation EGFR-TKI in order to provide data on treatment effect and sample size required for a future phase III trial.
In addition, the safety of the treatment combination will be evaluated.
Official Title
Conditions
Intervention / Treatment
- Drug: Amivantamab
- Drug: Lazertinib
- Drug: Zirabev
Other Study ID Numbers
- ETOP 18-21
- 2021-002337-42